Fluoroethyltyrosine for Evaluation of Intracranial Neoplasms

PHASE2CompletedINTERVENTIONAL
Enrollment

143

Participants

Timeline

Start Date

October 29, 2018

Primary Completion Date

March 31, 2024

Study Completion Date

March 31, 2024

Conditions
Intracranial NeoplasmLow Grade GliomaRecurrent GlioblastomaRecurrent World Health Organization (WHO) Grade II GliomaRecurrent WHO Grade III Glioma
Interventions
DRUG

F-18 Fluoroethyltyrosine (FET)

Patients given an injected dose of 4 to 7 millicurie (mCi) of FET per scan. The radiopharmaceutical will be administered while the patient is in the PET scanner

PROCEDURE

Positron Emission Tomography (PET)

All patients receive single PET imaging lasting for 40 minutes. Acquired PET data will be reconstructed so that three time points are created: (1) Perfusion: 60-second acquisition that starts immediately when activity is noted in the field of view, (2) Equilibrium: 10-minute acquisition acquired between 10 and 20 minutes after injection, and (3) Washout: 10-minute acquisition acquired between 30 and 40 minutes after injection. A repeat PET image will be offered to adult patients.

Trial Locations (1)

94115

University of California, San Francisco, San Francisco

All Listed Sponsors
lead

Thomas Hope

OTHER

NCT04044937 - Fluoroethyltyrosine for Evaluation of Intracranial Neoplasms | Biotech Hunter | Biotech Hunter